Mechanism-Based Management of B-Cell Non-Hodgkin Lymphomas: Novel Treatment Approaches Targeting PI3K, BTK, and EZH2

Mechanism-Based Management of B-Cell Non-Hodgkin Lymphomas: Novel Treatment Approaches Targeting PI3K, BTK, and EZH2

On-Demand Webcast

Nancy L. Bartlett, MD
Professor of Medicine
Washington University
St. Louis, Missouri

Jonathan W. Friedberg, MD, MMSc
Director, Wilmot Cancer Center
Professor of Medicine, University of Rochester
Rochester, New York

Richard R. Furman, MD
Morton Coleman, MD Distinguished Professor of Medicine
Weill Cornell Medicine
New York, New York

Brad S. Kahl, MD
Professor of Medicine
Washington University School of Medicine in St. Louis
St. Louis, Missouri

David G. Maloney, MD, PhD
Professor and Medical Director, Cellular Immunotherapy
Fred Hutchinson Cancer Research Center
Seattle, Washington

Peter Martin, MD
Associate Professor of Medicine
Weill Cornell Medicine
New York, New York

Jia Ruan, MD, PhD
Associate Professor of Clinical Medicine
Weill Cornell Medicine
New York, New York

Sarah Rutherford, MD
Assistant Professor of Medicine
Weill Cornell Medicine
New York, New York

Jennifer A. Woyach, MD
The Ohio State University
Columbus, Ohio


Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email


This educational activity is specifically designed for hematologists/oncologists, physician assistants, nurse practitioners, nurses, and pharmacists who specialize in hematology, as well as other healthcare providers who care for patients with hematologic malignancies.


Nearly 80,000 people in the United States will be diagnosed with non-Hodgkin lymphoma (NHL) in 2020. While there are at least 86 types of NHL that can arise from the clonal growth of B-cells, T-cells, natural killer (NK) cells, or the progenitors of these cells, about 85-90% of NHLs are derived from B-cells (B-NHLs)B-NHLs are further classified by morphology, immunophenotype, and genetic findings, with the most common subtypes being diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (MZL), and B-cell chronic leukemia/ small lymphocytic lymphoma (CLL/SLL)Chemotherapy and radiotherapy have long been used to treat B-NHLs with variable therapeutic outcomes, necessitating the development of new and effective treatment approaches. The B-cell receptor (BCR) is a critical component of B-cell survival, development and function and the dysregulation of the signaling pathway has been implicated in the lymphomagenesis and tumor survival for most B-NHLsAgents that target the BCR signaling pathways, as well as related epigenetic components of B-cell gene expression, have emerged as vital assets to the management of B-NHLs, particularly for treatment in the relapsed and refractory (R/R) setting. Selective inhibitors of Bruton’s tyrosine kinase (BTK), phosphatidylinositol-3 kinase (PI3K), and enhancer of zeste homolog 2 (EZH2) have become available as innovative targeted agents to improve outcomes for patients with B-NHLs. Education to provide clinicians with a comprehensive understanding of the agents that target the signaling and epigenetic factors of aberrant B-cell growth and function in B-NHLs is necessary to ensure patients are receiving personalized optimal treatments. 

This webcast aims to fill the gaps surrounding novel treatment approaches targeting PI3K, BTK, and EZH2 for the treatment of B-cell non-Hodgkin lymphomas.


After participating in this activity, learners should be better able to:

  • Describe the rationale for the treatment of B-NHLs with targeted inhibitors of BCR signaling and related epigenetic regulators of B-cell gene expression  
  • Evaluate available clinical data on the indications, efficacy, and adverse event (AE) profiles of available BTK, PI3K, and EZH2 inhibitors for the treatment of B-NHLs  
  • Create personalized treatment strategies for R/R B-NHLs based on individual pathological, genetic, and clinical factors that utilize targeted agents and rational combinations for optimal treatment outcomes 

To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: November 16, 2020
Expiration Date: November 16, 2021
Estimated Time to Complete: 3 hours

There is no fee associated with this activity.


Supported by an educational grant from: Bayer HealthCare Pharmaceuticals, Inc.



In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this internet enduring activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.


This continuing nursing education activity awards 3.00 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 3.00 contact hours. 


This internet enduring, knowledge-based activity (Universal Activity Number: JA0006201-0000-20-211-H01-P) has been approved for a maximum of 3.00 contact hours (.300 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, NACCME must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. NACCME is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 3.0 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.


This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Planning Committee

In addition to the faculty listed below, NACCME planners and staff include Christopher Bolwell, Samantha Conforti, Mary Johnson, Randy Robbin, Greaton Sellers, Shannon Stevenson, and Griselda Zuccarino-Catania. 

Christopher Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their products or services.

Griselda Zuccarino-Catania disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.

No other planner has disclosed a relevant financial relationship with any commercial interest.


The faculty has reported the following:

Nancy Bartlett: Advisory Board-ADC Therapeutics, Genentech/Roche, Seattle Genetics, Inc.; Grant/Research Support-ADC Therapeutics, Bristol Myers Squibb, Celgene, Forty Seven, Inc., Genentech/Roche, Immune Design, Janssen, Kite Pharma, Merck, Millenium, Pharmacyclics, Seattle Genetics, Inc.; Research Funding-Bristol Myers Squibb, Celgene, Forty Seven, Inc., Immune Design, Janssen, Kite Pharma, Merck, Millenium, Pharmacyclics, Seattle Genetics, Inc. 

Jonathan Friedberg: Advisory Board-Bayer; DSMB-Acerta Pharma, Novartis 

Richard Furman: Advisory Board-AbbVie, Acerta Pharma, AstraZeneca, BeiGene, Genentech/Roche, Janssen Pharmaceuticals, Loxo Oncology, MorphosysOncotracker, Pharmacyclics, Sanofi, Sunesis, TG Therapeutics, VerastemGrant/Research Support-Acerta Pharma, AstraZeneca, TG Therapeutics; DSMB-Incyte; Speakers Bureau-Janssen Pharmaceuticals; Speaker-Janssen Pharmaceuticals

Brad Kahl: Advisory Board-Genentech, Juno, Pharmacyclics; Consultant-AbbVie, Acerta/AstraZeneca, ADCT Therapeutics, Genentech, Juno, Pharmacyclics, Roche; DSMC-Roche; Grant/Research Support-ADCT Therapeutics

David Maloney: Advisory Board-A2 Biotherapeutics, Amgen, Celgene, Gilead, Juno Therapeutics, Kite Pharma, MorphoSys, Novartis, Pharmacyclics, Roche/Genentech; Consultant-Amgen, Bioline Rx, Celgene, Gilead, Juno Therapeutics, Kite Pharma, MorphoSys, Novartis, Pharmacyclics, Roche/Genentech; Grant/Research Support-Celgene, Juno Therapeutics, Kite Pharma; Research Funding-Celgene, Juno Therapeutics, Kite Pharma; Other-Bioline Rx, Juno Therapeutics

Peter Martin: Consultant-AstraZeneca, Bayer, BeiGene, Celgene, Cellectar, Janssen, Karyopharm, Kite, Morphosys, Regeneron, TeneobioVerastem; Grant/Research Support-Karyopharm

Jia Ruan: Advisory Board-Celgene/BMS; Consultant-Celgene/BMS, Kite Pharma; Grant/Research Support-AstraZeneca, Celgene/BMS, Pharmacyclics 

Sarah Rutherford: Advisory Board-AstraZeneca, Dova, Juno/Celgene, Karyopharm, Kite Pharma, Seattle Genetics; Grant/Research Support-Genentech, Karyopharm

Jennifer WoyachAdvisory Board-AbbVie, AstraZeneca, Janssen Pharmaceuticals, Morphosys, Pharmacyclics; Consultant-AstraZeneca, Janssen Pharmaceuticals, Pharmacyclics; Grant/Research Support-AbbVie, KaryopharmLoxo Oncology, MorphosysVerastem


North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.


NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.


Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Senior Manager/Director or the Executive Vice President, Chris Bolwell, Accreditation and Compliance, can be requested for a second level of review. Mr. Bolwell can be contacted via phone at 678-242-0801, by email at or in writing at 11675 Rainwater Drive, Suite 600 Alpharetta, GA 30009.